炎症性肠病经维多珠单抗治疗成功后出现严重脊柱关节炎相关附着点病变
该系列病例报告了11例接受维多珠单抗治疗且肠道病情控制良好的炎症性肠病患者,其中9例新发脊柱关节炎、2例已知脊柱关节炎 flare,4例因疾病严重需住院;中位 flare 时间为12周,7例中仅1例 HLA-B27 阳性,MRI 或超声可见严重附着点炎/骨炎,9例因关节炎严重停用维多珠单抗并更换治疗。
要点
- 维多珠单抗治疗 IBD 成功后,中位12周内可出现严重脊柱关节炎相关附着点炎/骨炎。
- 11例中9例为新发脊柱关节炎,2例为已知脊柱关节炎 flare,4例因严重程度住院。
- 影像学可见急性骶髂关节炎、广泛椎体骨炎、小关节周围水肿及孤立外周附着点炎。
核心结论
- 维多珠单抗成功治疗 IBD 后,可出现以 HLA-B27 阴性为主的严重脊柱关节炎伴骨炎/附着点炎,包括既往因肠道疾病使用过抗 TNF 治疗者。
研究设计与样本
- 研究评估了来自7个中心的11例接受维多珠单抗治疗的 IBD 患者,这些患者出现严重活动性脊柱关节炎和/或附着点病,旨在描述维多珠单抗相关的脊柱关节炎或附着点 flare,并记录显示特别严重疾病的影像学特征。
主要发现
- 11例中9例为新发脊柱关节炎,2例为已知脊柱关节炎 flare,4例因疾病严重需住院。
- 可获取数据的7例中1例 HLA-B27 阳性。
- 从维多珠单抗启动至 flare 的中位时间为12周,flare 时10例中7例 IBD 控制良好(1例无数据)。
- MRI 或超声显示严重脊柱关节炎附着点炎/骨炎,包括急性骶髂关节炎(n=5)、广泛椎体骨炎(n=1)、小关节周围水肿(n=1)和孤立外周附着点炎(n=3)。
- 因关节炎严重,11例中9例停用维多珠单抗并更换治疗,包括换用其他抗 TNF 药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. METHODS: We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. RESULTS: De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients, with 4 patients requiring hospitalization due to disease severity. Available data showed that one of seven cases were HLA-B27 positive. The median time from VDZ initiation to flare was 12 weeks, with IBD well controlled in 7 of 10 patients (no data for 1 patient) at flare. Severe SpA enthesitis/osteitis was evident on MRI or US, including acute sacroiliitis (n = 5), extensive vertebral osteitis (n = 1), peri-facetal oedema (n = 1) and isolated peripheral enthesitis (n = 3). Due to arthritis severity, VDZ was discontinued in 9 of 11 patients and a change in therapy, including alternative anti-TNF, was initiated. CONCLUSION: Severe SpA, predominantly HLA-B27 negative, with osteitis/enthesitis may occur under successful VDZ treatment for IBD, including in subjects with prior anti-TNF therapy for intestinal disease.
引用
- Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford). 2019. PMID: 30204909. doi:10.1093/rheumatology/key267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。